Your search for apixaban returned 4 results

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.